AMILORIDE FOR ERADICATION OF BURKHOLDERIA DOLOSA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要目的：评价多剂量阿米洛利雾化吸入(ASI)和妥布霉素雾化吸入(TSI)对囊性纤维化患者多发性伯克霍尔德菌呼吸道感染的疗效。 次要目标：1.测定囊性纤维化和多发性伯克霍尔德氏菌呼吸道感染患者多剂量ASI和TSI的安全性和耐受性。2.通过观察肺功能、痰菌落计数、肺恶化发生率、体重增加、生活质量评分和炎症标志物的变化，获得多剂量ASI和TSI治疗囊性纤维化和多发性伯克霍尔德氏菌呼吸道感染患者疗效的证据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective: Determination of the ability of multiple doses of amiloride solution for inhalation (ASI) and tobramycin solution for inhalation (TSI) to eradicate Burkholderia dolosa respiratory tract infection in patients with cystic fibrosis. Secondary Objectives: 1. Determination of the safety and tolerability of multiple doses of ASI and TSI in patients with cystic fibrosis and Burkholderia dolosa respiratory tract infection. 2. To obtain evidence of efficacy of multiple doses of ASI and TSI in patients with cystic fibrosis and Burkholderia dolosa respiratory tract infection as reflected in a change in pulmonary function, expectorated sputum bacterial colony counts, incidence of pulmonary exacerbations, weight gain, quality of life scores, and inflammatory markers.